Literature DB >> 466591

Clinical use of blood, blood components and blood products.

M A Blajchman, F A Shepherd, R A Perrault.   

Abstract

The goal of modern transfusion therapy is to provide appropriate replacement therapy with blood components as opposed to whole blood for patients with specific hematologic deficiencies. A prerequisite of component therapy is, therefore, correct identification of the deficiency. Appropriate use of components avoids many of the hazards associated with the use of whole blood, and at the same time makes maximal use of this valuable resource. Blood components separated from whole blood soon after collection and appropriately stored can, in combination, provide all the factors present in fresh whole blood. Red cell concentrates prepared from multiple packs have a hematocrit of approximately 70%. They may be stored for up to 3 weeks at 4 degrees C and are recommended for most situations requiring red cell transfusions. Platelet concentrates, which can be stored for up to 72 hours at 22 degrees C, may be used for thrombocytopenic patients. Fresh frozen plasma, stored plasma, cryoprecipitated factor VIII, factor VIII concentrate and factor IX complex concentrate are available for the proper treatment of patients with hemorrhagic disorders due to coagulation factor deficiencies. Similarly, albumin and immune serum globulin are available for their oncotic and antibody properties respectively. Thus, the availability and appropriate use of the various blood products allows not only optimal transfusion therapy for each patient, but also fuller utilization of national blood resources.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466591      PMCID: PMC1704176     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  29 in total

1.  HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

Authors:  J G POOL; E J GERSHGOLD; A R PAPPENHAGEN
Journal:  Nature       Date:  1964-07-18       Impact factor: 49.962

2.  Intravenous administration of human gamma-globulin.

Authors:  S BARANDUN; P KISTLER; F JEUNET; H ISLIKER
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

3.  McMaster conference on prevention of Rh immunization. 28-30 September, 1977.

Authors: 
Journal:  Vox Sang       Date:  1979       Impact factor: 2.144

Review 4.  Some aspects of recent advances in the use of blood cell components.

Authors:  C A Schiffer
Journal:  Br J Haematol       Date:  1978-07       Impact factor: 6.998

Review 5.  Blood replacement therapy.

Authors:  S J Urbaniak; J D Cash
Journal:  Br Med Bull       Date:  1977-09       Impact factor: 4.291

Review 6.  Fibrinogen--is the benefit worth the risk?

Authors:  J R Bove
Journal:  Transfusion       Date:  1978 Mar-Apr       Impact factor: 3.157

7.  Rh hemolytic disease of the newborn--the disease eradicated by immunology.

Authors:  A Zipursky
Journal:  Clin Obstet Gynecol       Date:  1977-09       Impact factor: 2.190

8.  Rh isoimmunization during pregnancy: antenatal prophylaxis.

Authors:  J M Bowman; B Chown; M Lewis; J M Pollock
Journal:  Can Med Assoc J       Date:  1978-03-18       Impact factor: 8.262

9.  Frozen autologous platelet transfusion for patients with leukemia.

Authors:  C A Schiffer; J Aisner; P H Wiernik
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

10.  Relative hemostatic effectiveness of human platelets stored at 4 degrees and 22 degrees C.

Authors:  D J Filip; R H Aster
Journal:  J Lab Clin Med       Date:  1978-04
View more
  3 in total

Review 1.  Blood component therapy in anaesthetic practice.

Authors:  M A Blajchman; R Herst; R A Perrault
Journal:  Can Anaesth Soc J       Date:  1983-07

2.  Craniosynostosis: an assessment of blood loss and transfusion practices.

Authors:  R A Kearney; J K Rosales; W J Howes
Journal:  Can J Anaesth       Date:  1989-07       Impact factor: 5.063

3.  A discrete-event simulation model for analysing and improving operations in a blood donation centre.

Authors:  Martina Doneda; Semih Yalçındağ; Inês Marques; Ettore Lanzarone
Journal:  Vox Sang       Date:  2021-05-06       Impact factor: 2.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.